The anti-cancer drug paclitaxel (Taxol) alters microtubule assembly and activates pro-apoptotic signaling pathways. Previously, we and others found that paclitaxel activates endogenous JNK in tumor cells, and the activation of JNK contributes to tumor cell apoptosis. Here we find that paclitaxel activates the prosurvival MEK/ERK pathway, which conversely may compromise the efficacy of paclitaxel. Hence, a combination treatment of paclitaxel and MEK inhibitors was pursued to determine if this treatment could lead to enhanced apoptosis. The inhibition of MEK/ERK with a pharmacologic inhibitor, U0126 together with paclitaxel resulted in a dramatic enhancement of apoptosis that is 4X more than the additive value of the two drugs alone. Enhanced apoptosis was verified by the terminal transferase-mediated dUTP nick end-labeling (TUNEL) assay, by an ELISA assay for histone-associated DNA fragments, and by flow cytometric analysis for DNA content. Specificity of the pharmacologic inhibitor was confirmed by the use of (a) a second MEK/ERK inhibitor, and (b) a transdominant-negative MEK. Enhanced apoptosis was verified in breast, ovarian, and lung tumor cell lines, suggesting this effect is not cell-type specific. This is the first report of enhanced apoptosis detected in the presence of paclitaxel and MEK inhibition and suggests a new anticancer strategy.
INTRODUCTION
Paclitaxel is a promising frontline chemotherapy in the treatment of patients with ovarian, breast, and non-small cell lung carcinomas (NSCLC) 4 (1-3). Paclitaxel is isolated from the bark of the pacific yew (Taxus brevifolia), and functions by binding and stabilizing microtubules (4) . Binding of paclitaxel to microtubules blocks normal cell cycle progression during the merger of mitotic metaphase and anaphase. This prevents chromosome segregation, leading to tumor cell death.
Combination therapy of paclitaxel and Herceptin, an anti-Her2-neu antibody, has produced impressive responses among breast cancer patients (5, 6) , although this combination is obviously limited to Her2-neu+ tumors. Combination therapy with other drugs, preferably via a rational molecular basis that is widely applicable to many tumor types, is essential for improved cancer treatment. A combination of paclitaxel with reagents that activate additional apoptotic signals, or inhibit survival signals may provide a rational molecular basis for novel chemotherapeutic strategies.
A rational molecular target is the ERK mitogen-activated protein (MAP) kinase pathway that may serve as an opposing force to Jun N-terminal kinase (JNK/SAPK).
Previous reports have shown that JNK/SAPK leads to cell death, while MEK activation contributes to cell differentiation, proliferation and survival (7, 8) . Activated Raf-1, a serine-threonine kinase, initiates the signaling cascade through MEK, which in turn phosphorylates a second serine-threonine kinase ERK. ERK phosphorylates additional kinases and specific transcription factors, such as Elk-1 and c-Fos, which are important in cell proliferation. However, the link between Raf-1 and ERK activation and paclitaxelinduced cell death is not straightforward. Several studies have shown that at a low by guest on November 14, 2017 http://www.jbc.org/ Downloaded from concentration of the drug, paclitaxel-mediated apoptosis is attributed to activated Raf-1 (9) (10) (11) . The role of the downstream ERK MAP kinase in paclitaxel-induced tumor apoptosis is also not entirely clear (12) (13) (14) (15) (16) (17) .
In this report, we tested the combined effects of paclitaxel and inhibitors of MEK1/2 kinase on tumor cell apoptosis. The specificity of MEK1/2 inhibition was achieved by using two different MEK inhibitors, and by the additional use of transdominant-negative mutants, which inhibit MEK/ERK activation. The reasons for selecting MEK1/2 as the target are: (i) MEK is activated in many tumors (18) (19) (20) ; (ii) small molecule-based MEK inhibitors are readily available and a recent report has described a novel MEK inhibitor that exhibited in vivo efficacy in mice (21) (22) (23) ; and (iii)
MEK is critical in transforming cells, leading to tumor survival and proliferation (24, 25) .
In the present study, we show that paclitaxel increases MEK1/2 activity. The combined treatment of paclitaxel plus MEK1/2 inhibition leads to enhanced cell death in breast, ovarian, and lung tumor lines. the samples were centrifuged and 20µl of the supernatant transferred to a streptavidincoated microtiter plate. Anti-histone biotin and anti-DNA peroxidase antibodies were added to each well and the plate was incubated at room temperature for 2 hours. After three washes with incubation buffer, the peroxidase substrate was added to each well.
Following a fifteen-minute incubation, the plates were read at 405nm in a microplate reader. The data in this report are expressed as fold increase in optical density as compared to control treated cells. 
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RESULTS AND DISCUSSION
The effect of paclitaxel on JNK and ERK activities is shown in Figure 1 . Basal JNK activity was detected, and this activity was significantly enhanced by treatment with low, nanomolar doses of paclitaxel in human lung and breast carcinoma cell lines (Fig.   1A) . A basal level of ERK was also detected, and low doses of paclitaxel activated endogenous ERK1 and ERK2 (Fig. 1B) . The MEK inhibitor, U0126, completely blocked ERK activation by paclitaxel. The activation of JNK in this scenario has been previously found to contribute to apoptosis, while the role of paclitaxel-induced ERK has not been studied. In other systems, ERK generally plays a critical role in cell proliferation and growth (26, 27) ; thus, it was reasoned that ERK activation by paclitaxel might enhance cell proliferation and compromise the efficacy of this drug. A logical approach is to use pharmacologic blockers of MEK to inhibit paclitaxel-induced ERK activation and its downstream effects.
To test this hypothesis, a combination of paclitaxel and a potent MEK1 inhibitor, U0126, was used to treat a variety of human carcinoma lines, and cell death was measured by the cell death detection ELISA assay that detects DNA-histone fragmentation. The combination of paclitaxel plus U0126 enhanced cell death ( Fig. 2A) . The fold increase in apoptosis was calculated by comparing the ELISA optical density readings of treated samples, with the value of the untreated control as 1.0. In H157 cells, paclitaxel and U0126 combined caused 4X more cell death than paclitaxel alone, and 8X more cell death than U0126 alone. A similar trend was observed in OVCA194 cells.
The potential use of low-dose chemotherapy is important because lower dosages are more attainable during cancer therapy and likely to cause less toxicity in patients. We performed a dose-response analysis to assess the minimal concentration of paclitaxel, which when combined with U0126, causes enhanced cell death. Low-doses of paclitaxel, starting at the 10 nM range, combined with U0126 cause enhanced cell death in both BT474 breast and H157 lung carcinoma cells (Fig. 2B ).
To control for pharmacologic specificity, two additional experiments were performed. First, a second MEK inhibitor PD98059 was used and produced similar data (Fig. 2C) , providing additional evidence that the MEK enzyme is the target. However, pharmacologic approaches have their limitations, because the specificity of the drug can always be questioned. To provide further evidence for the effects of MEK inhibition, a dominant-negative MEK (dnMEK) mutant was introduced into H157 cells. Expression of dnMEK in the presence of low-dose (50nM and 250nM) paclitaxel enhanced apoptosis over the pCMV empty vector control (Fig. 2D) . Table 1 summarizes enhanced apoptosis observed with paclitaxel and U0126. In H157 and OVCA194 cells, the combination treatment produced 4.0 and 2.5-fold enhancement of apoptosis over the expected additive effect. This enhancement was achieved with relative low-dosages (1 µM paclitaxel, 10 µM of U0126) of these two drugs. This trend was also observed with the breast carcinoma BT474 (not shown).
To examine the mechanism of U0126 and paclitaxel induced cell death, their effects on cell cycle progression was studied. The BT474 breast carcinoma cells were treated with paclitaxel and/or U0126, and cell cycle progression was analyzed by incubating the cells with propidium iodide, which allowed the analysis of DNA content by flow cytometry. U0126 arrested BT474 cells in G1, while 10nM paclitaxel produced a dramatic G2 block (Fig. 3A) . The percentage of control treated cells in G2-M was 13%, which increased to 75% after treatment with 10nM paclitaxel for 24 hours. Seventeen percent of the cells underwent apoptosis in the presence of paclitaxel, while a negligible increase in cell death was detected in the presence of U0126 when compared to the control (6% compared to 4%). In contrast, the combination of paclitaxel and U0126 substantially increased cell death as evidence by accumulation of a sub-G1 population that has < 2N DNA (Fig. 3A) and represents dead cells. These results further support the ELISA result that low-doses of paclitaxel and U0126 enhanced tumor cell death.
To assess if the cell death observed above represents apoptosis, a TUNEL assay was performed with paclitaxel, U0126, or a combination of the two drugs. Singly, 
